EHA 2026 preview – Bristol’s celmod reveal

18 May 2026

Golcadomide and iberdomide are set to feature at EHA.

While most of the abstracts for the upcoming European Hematology Association congress are now available to view, mystery surrounds two presentations covering Bristol Myers Squibb’s cereblon modulators golcadomide and iberdomide. Neither has a plenary slot, but both remained embargoed as of 18 May.Also under wraps for now is the Frontmind trial of Incyte’s Monjuvi, toplined positive in January and due to be presented at EHA’s Saturday plenary session. Meanwhile, among EHA’s regular oral presentations interest could fall on a type II JAK2 inhibitor whose originator, Ajax, was acquired by Lilly just last month.ApexOnco separately covered another key EHA plenary, the Monumental-3 trial of Johnson & Johnson’s Talvey, for which abstract data have already been made public. The same goes for presentations of the rival BTK degraders bexobrutideg (from Nurix) and BGB-16673 (BeOne), though it’s possible that more mature results, including safety data, will be presented at EHA.Meanwhile, nothing is known about late-breaking EHA presentations, with neither the abstract texts nor titles having been made public yet.Celmod secrecyIt’s not clear why EHA has so far kept back Bristol’s golcadomide and iberdomide abstracts. It’s not been disclosed what study of the former is to be presented at EHA, although it's in first-line B-cell lymphoma.Iberdomide, a possible replacement for the off-patent Revlimid, is awaiting a 17 August FDA decision on its approvability for relapsed/refractory multiple myeloma, and the EHA presentation concerns its Ideal study, in front-line disease. EHA will also see data on another Bristol multiple myeloma project, the anti-GPRC5D Car-T arlocabtagene autoleucel.  Selected EHA 2026 presentationsProjectMechanismCompanySettingAbstractFri 12 JunOfirnoflastNEK7 inhibitorHalia TherapeuticsLow-risk MDSS174Favezelimab + pembro FDCLag3/PD-1 MAb coformulationMerck & CoR/r Hodgkin’s lymphomaS220Vispa-celCD19 Car-T (allo)CaribouR/r NHLS236GolcadomideCereblon modulatorBristol Myers Squibb1st-line B-cell lymphomaS239*Sat 13 JunMonjuviCD19 MAbIncyte (ex Novartis)1st-line DLBCLS101 (plenary)*TecvayliBCMA T-cell engagerJ&J1st-line multiple myeloma maintenance, +/- RevlimidS197IberdomideCereblon modulatorBristol Myers Squibb1st-line multiple myelomaS199*INCA033989CALRmut MAbIncyteR/r myelofibrosisS216BezuclastinibKIT inhibitorCogent BiosciencesAdvanced systemic mastocytosisS217AJ1-11095Type II JAK2 inhibitorLilly (ex Ajax)Myelofibrosis after failure on type I JAK2 inhibitionS218Sun 14 JunArlo-celGPRC5D Car-TBristol Myers Squibb2nd-4th line multiple myelomaS200CB-011BCMA Car-T (allo)Caribou4th-line+ multiple myelomaS201OL-101GPRC5D x BCMA Car-TOverland TherapeuticsMultiple myeloma post GPRC5D or BCMAS285PMB-CT01BAFF-R Car-TPeproMeneR/r B-cell lymphoma post CD19S287Notes: late-breaking abstracts not revealed as at 18 May; *no abstract text available as at 18 May. For Lilly the Ajax move was one of several recent oncology acquisitions, bringing in the type II JAK2 inhibitor AJ1-11095, for which proof-of-concept data were promised later this year.These data, to be presented at EHA, concern 20 myelofibrosis patients who had failed on Novartis/Incyte’s Jakafi, with the abstract revealing 13 of these reaching 35% or greater spleen volume reduction (SVR35) after 12 weeks; two others attained SVR35 in dose escalation. The Ajax takeover was said to be worth $2.3bn, but the up-front amount wasn’t disclosed.Incyte itself will have myelofibrosis data at EHA, from two studies of its anti-CALRm MAb INCA033989, earlier detailed at last year’s ASH conference. As for trials toplined positive but yet to report full results, the Apex study of Cogent’s KIT inhibitor bezuclastinib in advanced systemic mastocytosis will be presented on 13 June; a US filing is due to be submitted in the second half.At least one company isn’t shying away from presenting negative data, with Merck & Co set to feature the Keyform-008 study of the anti-Lag3 MAb favezelimab coformulated with pembrolizumab on 12 June. Favezelimab was discontinued in December 2024, and the Lag3 mechanism has continued to disappoint, with Regeneron revealing the phase 3 failure of fianlimab in first-line melanoma just last week.Keyform-008 concerned relapsed Hodgkin’s lymphoma, and the EHA abstract shows a technical win versus chemo on PFS (HR=0.757, p=0.0462), a result said to “warrant cautious interpretation”; there’s also a numerical trend on OS, but response rates are notably higher with chemo (68%) than with the Merck combo (44%).Elsewhere, Legend investors might be hoping for first data with that company’s in vivo Car-T therapy LVIVO-TaVec100/LB2501, which targets CD19 and CD20, and which Evercore ISI analysts have said might be coming at EHA. However, no abstracts revealed so far concern this project, leaving the possibility that results might come in one of the still undisclosed late-breakers.The 2026 EHA congress takes place in Stockholm on 11-14 June.

Also under wraps for now is the Frontmind trial of Incyte’s Monjuvi, toplined positive in January and due to be presented at EHA’s Saturday plenary session. Meanwhile, among EHA’s regular oral presentations interest could fall on a type II JAK2 inhibitor whose originator, Ajax, was acquired by Lilly just last month.

ApexOnco separately covered another key EHA plenary, the Monumental-3 trial of Johnson & Johnson’s Talvey, for which abstract data have already been made public. The same goes for presentations of the rival BTK degraders bexobrutideg (from Nurix) and BGB-16673 (BeOne), though it’s possible that more mature results, including safety data, will be presented at EHA.

Meanwhile, nothing is known about late-breaking EHA presentations, with neither the abstract texts nor titles having been made public yet.

Celmod secrecy

It’s not clear why EHA has so far kept back Bristol’s golcadomide and iberdomide abstracts. It’s not been disclosed what study of the former is to be presented at EHA, although it's in first-line B-cell lymphoma.

Iberdomide, a possible replacement for the off-patent Revlimid, is awaiting a 17 August FDA decision on its approvability for relapsed/refractory multiple myeloma, and the EHA presentation concerns its Ideal study, in front-line disease. EHA will also see data on another Bristol multiple myeloma project, the anti-GPRC5D Car-T arlocabtagene autoleucel.

Selected EHA 2026 presentations

Project	Mechanism	Company	Setting	Abstract
Fri 12 Jun
Ofirnoflast	NEK7 inhibitor	Halia Therapeutics	Low-risk MDS	S174
Favezelimab + pembro FDC	Lag3/PD-1 MAb coformulation	Merck & Co	R/r Hodgkin’s lymphoma	S220
Vispa-cel	CD19 Car-T (allo)	Caribou	R/r NHL	S236
Golcadomide	Cereblon modulator	Bristol Myers Squibb	1st-line B-cell lymphoma	S239*
Sat 13 Jun
Monjuvi	CD19 MAb	Incyte (ex Novartis)	1st-line DLBCL	S101 (plenary)*
Tecvayli	BCMA T-cell engager	J&J	1st-line multiple myeloma maintenance, +/- Revlimid	S197
Iberdomide	Cereblon modulator	Bristol Myers Squibb	1st-line multiple myeloma	S199*
INCA033989	CALRmut MAb	Incyte	R/r myelofibrosis	S216
Bezuclastinib	KIT inhibitor	Cogent Biosciences	Advanced systemic mastocytosis	S217
AJ1-11095	Type II JAK2 inhibitor	Lilly (ex Ajax)	Myelofibrosis after failure on type I JAK2 inhibition	S218
Sun 14 Jun
Arlo-cel	GPRC5D Car-T	Bristol Myers Squibb	2nd-4th line multiple myeloma	S200
CB-011	BCMA Car-T (allo)	Caribou	4th-line+ multiple myeloma	S201
OL-101	GPRC5D x BCMA Car-T	Overland Therapeutics	Multiple myeloma post GPRC5D or BCMA	S285
PMB-CT01	BAFF-R Car-T	PeproMene	R/r B-cell lymphoma post CD19	S287

Notes: late-breaking abstracts not revealed as at 18 May; *no abstract text available as at 18 May.

For Lilly the Ajax move was one of several recent oncology acquisitions, bringing in the type II JAK2 inhibitor AJ1-11095, for which proof-of-concept data were promised later this year.

These data, to be presented at EHA, concern 20 myelofibrosis patients who had failed on Novartis/Incyte’s Jakafi, with the abstract revealing 13 of these reaching 35% or greater spleen volume reduction (SVR35) after 12 weeks; two others attained SVR35 in dose escalation. The Ajax takeover was said to be worth $2.3bn, but the up-front amount wasn’t disclosed.

Incyte itself will have myelofibrosis data at EHA, from two studies of its anti-CALRm MAb INCA033989, earlier detailed at last year’s ASH conference. As for trials toplined positive but yet to report full results, the Apex study of Cogent’s KIT inhibitor bezuclastinib in advanced systemic mastocytosis will be presented on 13 June; a US filing is due to be submitted in the second half.

At least one company isn’t shying away from presenting negative data, with Merck & Co set to feature the Keyform-008 study of the anti-Lag3 MAb favezelimab coformulated with pembrolizumab on 12 June. Favezelimab was discontinued in December 2024, and the Lag3 mechanism has continued to disappoint, with Regeneron revealing the phase 3 failure of fianlimab in first-line melanoma just last week.

Keyform-008 concerned relapsed Hodgkin’s lymphoma, and the EHA abstract shows a technical win versus chemo on PFS (HR=0.757, p=0.0462), a result said to “warrant cautious interpretation”; there’s also a numerical trend on OS, but response rates are notably higher with chemo (68%) than with the Merck combo (44%).

Elsewhere, Legend investors might be hoping for first data with that company’s in vivo Car-T therapy LVIVO-TaVec100/LB2501, which targets CD19 and CD20, and which Evercore ISI analysts have said might be coming at EHA. However, no abstracts revealed so far concern this project, leaving the possibility that results might come in one of the still undisclosed late-breakers.

The 2026 EHA congress takes place in Stockholm on 11-14 June.